Back to top
more

Catalent, Inc. (CTLT)

(Delayed Data from NYSE)

$45.79 USD

45.79
938,248

+1.37 (3.08%)

Updated May 3, 2019 04:02 PM ET

After-Market: $45.80 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Brokerage Reports

[CTLT]

Reports for Purchase

Showing records 161 - 180 ( 223 total )

Industry: Medical - Drugs

Record: 161

02/03/2020

Daily Note

Pages: 3

Wow, That Was Quick

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 162

02/03/2020

Company Report

Pages: 6

Gene Therapy or Bust

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 163

01/09/2020

Daily Note

Pages: 64

2020 Outlook: Healthcare IT / Digital Health and CRO / Biopharma Outsourcing

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 150.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 164

01/09/2020

Daily Note

Pages: 5

Research Summary

Provider: KEYBANC CAPITAL MARKETS

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 165

11/13/2019

Daily Note

Pages: 26

Biopharma Software and Services: 3Q19 Post Mortem

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 166

11/12/2019

Daily Note

Pages: 6

Tech Morning Call

Provider: KEYBANC CAPITAL MARKETS

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 167

11/12/2019

Daily Note

Pages: 9

Morning Call

Provider: KEYBANC CAPITAL MARKETS

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 168

11/11/2019

Daily Note

Pages: 26

Biopharma Software and Services: 3Q19 Post Mortem

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 169

08/28/2019

Daily Note

Pages: 5

Tech Morning Call

Provider: KEYBANC CAPITAL MARKETS

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 170

08/28/2019

Daily Note

Pages: 7

Morning Call

Provider: KEYBANC CAPITAL MARKETS

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 171

08/27/2019

Company Report

Pages: 6

Hat Tip (and Downgrading)

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 172

05/07/2019

Company Report

Pages: 5

Looking Ahead to FY20

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 173

05/07/2019

Daily Note

Pages: 9

Research Summary

Provider: KEYBANC CAPITAL MARKETS

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 174

04/15/2019

Company Report

Pages: 5

Gene Therapy Land Grab

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 175

04/15/2019

Daily Note

Pages: 8

Morning Call

Provider: KEYBANC CAPITAL MARKETS

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 176

04/15/2019

Daily Note

Pages: 5

Research Summary

Provider: KEYBANC CAPITAL MARKETS

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 177

04/15/2019

Daily Note

Pages: 5

Tech Morning Call

Provider: KEYBANC CAPITAL MARKETS

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 178

04/14/2019

Daily Note

Pages: 3

Wow, ~6x Revenue

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 179

03/25/2019

Daily Note

Pages: 3

Wow, 6.8x Revenue

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOSELTON B

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 180

02/05/2019

Company Report

Pages: 5

What a Difference a Quarter Makes

Provider: KEYBANC CAPITAL MARKETS

Analyst: HOOKER D

Price: 10.00

Research Provided by a Third Party